[go: up one dir, main page]

WO2009074678A3 - Anticancer conjugates of camptothecin to hyaluronic acid - Google Patents

Anticancer conjugates of camptothecin to hyaluronic acid Download PDF

Info

Publication number
WO2009074678A3
WO2009074678A3 PCT/EP2008/067433 EP2008067433W WO2009074678A3 WO 2009074678 A3 WO2009074678 A3 WO 2009074678A3 EP 2008067433 W EP2008067433 W EP 2008067433W WO 2009074678 A3 WO2009074678 A3 WO 2009074678A3
Authority
WO
WIPO (PCT)
Prior art keywords
camptothecin
hyaluronic acid
linker
conjugates
ester bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/067433
Other languages
French (fr)
Other versions
WO2009074678A2 (en
Inventor
Stefano Norbedo
Francesca Dinon
Susanna Bosi
Massimo Bergamin
Erminio Murano
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Pharmaceuticals Holdings Ireland ULC
Original Assignee
Eurand Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Pharmaceuticals Ltd filed Critical Eurand Pharmaceuticals Ltd
Publication of WO2009074678A2 publication Critical patent/WO2009074678A2/en
Publication of WO2009074678A3 publication Critical patent/WO2009074678A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

New conjugates are described, containing camptothecin connected to hyaluronic acid via a linker, where the linker is bound to the hyaluronic acid by means of an ester bond. The ester bond involves on one side, a hydroxyl group of hyaluronic acid and, on the other side, a carboxyl group present on the linker; the linker is covalently bonded to camptothecin. Pharmaceutical compositions thereof, their use in the treatment of pathologies responsive to camptothecin, and a process to prepare said conjugates are also described.
PCT/EP2008/067433 2007-12-12 2008-12-12 Anticancer conjugates of camptothecin to hyaluronic acid Ceased WO2009074678A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE20070900A IE20070900A1 (en) 2007-12-12 2007-12-12 New anticancer conjugates
IE2007/0900 2007-12-12

Publications (2)

Publication Number Publication Date
WO2009074678A2 WO2009074678A2 (en) 2009-06-18
WO2009074678A3 true WO2009074678A3 (en) 2009-08-13

Family

ID=40627359

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/067433 Ceased WO2009074678A2 (en) 2007-12-12 2008-12-12 Anticancer conjugates of camptothecin to hyaluronic acid

Country Status (2)

Country Link
IE (1) IE20070900A1 (en)
WO (1) WO2009074678A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279287A (en) * 2016-08-12 2017-01-04 华中科技大学 A kind of camptothecine phosphate compounds, its preparation method and application
CN106279285A (en) * 2016-08-12 2017-01-04 华中科技大学 A kind of camptothecine phosphate compounds, its preparation method and application

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010053140A1 (en) 2008-11-05 2010-05-14 国立大学法人 東京医科歯科大学 Hyaluronic acid derivative and pharmaceutical composition thereof
CN102649810A (en) * 2011-05-19 2012-08-29 东北林业大学 Camptothecin derivative and preparation method and application thereof
BR112015004501B1 (en) 2012-09-05 2021-04-13 Chugai Seiyaku Kabushiki Kaisha HYALURONIC ACID DERIVATIVE HAVING AMINO ACIDS AND STERILE GROUPS INTRODUCED IN THE SAME AND PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT
US9962452B2 (en) * 2013-02-04 2018-05-08 Zhuhai Beihai Biotech Co., Ltd. Soluble complexes of drug analogs and albumin
HRP20220176T1 (en) 2014-02-27 2022-04-29 Synartro Ab Hyaluronan conjugates with pharmaceutically active substances, methods and compositions
CZ305153B6 (en) * 2014-03-11 2015-05-20 Contipro Biotech S.R.O. Conjugates of hyaluronic acid oligomer or a salt thereof, process for their preparation and use
WO2015200837A1 (en) 2014-06-27 2015-12-30 Fl Therapeutics Llc Abiraterone derivatives and non-covalent complexes with albumin
WO2016065139A1 (en) 2014-10-24 2016-04-28 Fl Therapeutics Llc 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin
JP6026708B1 (en) * 2015-01-09 2016-11-16 生化学工業株式会社 Chondroitin sulfate derivative and bladder disease treatment agent
EP3267975A4 (en) * 2015-03-09 2018-08-08 The Regents of the University of California Polymer-drug conjugates for combination anticancer therapy
GB201612872D0 (en) * 2016-07-25 2016-09-07 Univ Of Manchester The Prodrug compounds
JP7221211B2 (en) 2017-11-15 2023-02-13 中外製薬株式会社 Hyaluronic Acid Derivatives Modified with Polyethylene Glycol
MY208431A (en) * 2019-06-03 2025-05-08 Aihol Corp Hyaluronan conjugates and uses thereof
JP2023533679A (en) * 2020-07-15 2023-08-04 コヴァル バイオファーマ （シャンハイ） カンパニー，リミテッド Drug delivery systems and their use for the local delivery of therapeutic agents
WO2024110843A1 (en) 2022-11-21 2024-05-30 Segena Corporation S.A. Enhancing oligonucleotide immunomodulatory activity through dianophore long-lasting modification: methods and applications
CN119454616B (en) * 2024-12-02 2025-10-31 哈尔滨医科大学 Drug-loaded microsphere for interventional therapy of liver cancer and preparation method thereof
CN119857152B (en) * 2025-03-25 2025-06-10 合肥工业大学 A phospholipid complex delivery system and its preparation method and application

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035721A1 (en) * 1995-05-10 1996-11-14 Fidia Advanced Biopolymers S.R.L. A dicarboxylic acid hemiester or hemiamide with a pharmacologically active compound and with hyaluronic acid or with a hyaluronic acid ester, a process for its preparation and a controlled release medicament containing this derivative
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
WO2007014784A2 (en) * 2005-08-03 2007-02-08 Fidia Farmaceutici S.P.A. Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2007085629A2 (en) * 2006-01-25 2007-08-02 Eurand Pharmaceuticals Ltd. Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996035721A1 (en) * 1995-05-10 1996-11-14 Fidia Advanced Biopolymers S.R.L. A dicarboxylic acid hemiester or hemiamide with a pharmacologically active compound and with hyaluronic acid or with a hyaluronic acid ester, a process for its preparation and a controlled release medicament containing this derivative
WO2004035629A2 (en) * 2002-10-18 2004-04-29 Fidia Farmaceutici S.P.A. Taxanes covalently bounded to hyaluronic acid or hyaluronic acid derivatives
WO2006122954A2 (en) * 2005-05-18 2006-11-23 Eurand Pharmaceuticals Limited Antiproliferative conjugates comprising hyaluronic acid and n-derivatives of glutamic acid
WO2007014784A2 (en) * 2005-08-03 2007-02-08 Fidia Farmaceutici S.P.A. Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation
WO2007085629A2 (en) * 2006-01-25 2007-08-02 Eurand Pharmaceuticals Ltd. Use of hyaluronic acid as a carrier molecule for?different classes of therapeutic active agents

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106279287A (en) * 2016-08-12 2017-01-04 华中科技大学 A kind of camptothecine phosphate compounds, its preparation method and application
CN106279285A (en) * 2016-08-12 2017-01-04 华中科技大学 A kind of camptothecine phosphate compounds, its preparation method and application
CN106279287B (en) * 2016-08-12 2018-11-30 华中科技大学 A kind of camptothecine phosphate compounds, preparation method and application
CN106279285B (en) * 2016-08-12 2018-11-30 华中科技大学 A kind of camptothecine phosphonate ester compound, preparation method and application

Also Published As

Publication number Publication date
IE20070900A1 (en) 2009-06-24
WO2009074678A2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
WO2009074678A3 (en) Anticancer conjugates of camptothecin to hyaluronic acid
UA91575C2 (en) Four branched dendrimer-peg for conjugation to proteins and peptides
EP2019122A4 (en) Polymer conjugate of podophyllotoxin
WO2008103693A3 (en) Chemical linkers with single amino acids and conjugates thereof
EP2497785A3 (en) Hyaluronic acid derivative and drug containing the same
WO2010122385A8 (en) Fast-acting insulin formulation
WO2009041570A1 (en) Polymer conjugate of steroid
NZ612320A (en) Materials and methods for conjugating a water soluble fatty acid derivative to a protein
WO2008073162A3 (en) Lysine acetylation sites
UA98153C2 (en) Cytotoxic agent comprising tomaymycin derivatives and their therapeutic use
WO2009141826A3 (en) Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases
WO2008106186A3 (en) Activated polyoxazolines and compositions comprising the same
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2009102820A3 (en) Modified sugar substrates and methods of use
WO2011013130A3 (en) Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof
WO2010033220A3 (en) Modified therapeutics peptides, methods of their preparation and use
WO2011015634A3 (en) Controlled release formulations of lipocalin muteins
JP2012528857A5 (en)
MY156872A (en) Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011112482A3 (en) Polymeric drug delivery conjugates and methods of making and using thereof
EP3281956A3 (en) Human antibody drug conjugates against tissue factor
EP3406347A3 (en) Xten conjugate compositions and methods of making same
WO2010107487A3 (en) Lipid-drug conjugates for drug delivery
MY159197A (en) Anticancer derivatives, preparation thereof and therapeutic use thereof
WO2013067199A3 (en) Subcutaneous delivery of polymer conjugates of therapeutic agents

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859925

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859925

Country of ref document: EP

Kind code of ref document: A2